Eiger BioPharmaceuticals (NASDAQ:EIGR) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

The firm has a market capitalization of $2.55 million, a P/E ratio of -0.03 and a beta of 1.83. The firm has a 50-day moving average price of $4.77 and a 200 day moving average price of $6.98. Eiger BioPharmaceuticals has a 1 year low of $1.10 and a 1 year high of $43.35.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.